Portola Pharma (PTLA) Misses Q1 EPS by 9c

Portola Pharma (NASDAQ: PTLA) reported Q1 EPS of ($1.15), $0.09 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $7.91 million.

For earnings history and earnings-related data on Portola Pharma (PTLA) click here.

You May Also Be Interested In

• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance
• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• RBC Capital Downgrades GQG Partners Inc (GQG:AU) to Sector Perform